Ratings TOKAI Corp.

Equities

9729

JP3552250007

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-10 am EDT			5-day change	1st Jan Change
2,126 ^JPY	+0.19%		+0.38%	+1.72%

May. 06	Tokai Tokyo Financial to Merge Two Consolidated Subsidiaries	MT
May. 02	Tokai Tokyo Financial's Attributable Profit Soars 422% in Fiscal 2023	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

The company appears to be poorly valued given its net asset value.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company is highly valued given the cash flows generated by its activity.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
TOKAI CORP.	+1.72%	480M		-
HENRY SCHEIN, INC.	-3.00%	9.4B		B+
SHIP HEALTHCARE HOLDINGS, INC.	-0.44%	1.42B		D
OWENS & MINOR, INC.	-5.19%	1.41B		B+
AS ONE CORPORATION	-5.79%	1.2B		-
GKHT MEDICAL TECHNOLOGY CO., LTD.	-14.59%	921M	-	-
EXCELSIOR MEDICAL CO., LTD.	+3.85%	441M	-	-
GAUSH MEDITECH LTD	-48.41%	378M		-
COWEALTH MEDICAL CHINA CO.,LTD.	-19.75%	363M	-	-
WIN-PARTNERS CO., LTD.	-2.93%	215M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes